drugset / Trial / NCT02041273

Relative Bioavailability Of Palbociclib (PD-0332991) Under Fed And Fasted Conditions

NCT02041273

Phase 1 Completed 36 enrolled Pfizer
NaSingle-groupOpen-labelBasic science

Summary

A relative bioavailability study of commercial palbociclib free base hard capsules to the isethionate salt palbociclib capsules ( used in Phase 1 and 2 studies) under different fasting conditions.

Timeline

Start
2014-01
Primary completion
2014-03
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Palbociclib Small molecule 125 mg

Indications

No indication recorded.